Korea / KHIDI President Talks Domestic Vaccine R&D
KHIDI’s Soonman KWON outlines the public health R&D funding landscape in Korea, plans to increase Korea’s capacity to develop and produce its own vaccines in the wake of the COVID-19…
Korea Health Industry Development Institute (KHIDI) is a government-affiliated institution which performs professional and systematic support to develop domestic health industry and enhance health services.
Since its establishment in 1999, KHIDI has led expansion of healthcare R&D investment and building competitiveness of Korea’s healthcare industry, i.e., health services, pharmaceuticals, medical devices, food and beauty-cosmetic. We are also witnessing rapid growth of global healthcare sector – especially in attracting foreign patients and exporting healthcare service providers along with healthcare systems. This is a valuable outcome we have earned through years of efforts on global advancement and outreach in this sector.Since its establishment in 1999, KHIDI has been playing a major role in the industry development as the nation’s only one organization responsible for fostering health industry. While we have striven to produce more successful research outcomes by means of greater investments in Health Technology (HT) R&D, KHIDI also took the initiative in increasing competitiveness in different areas of health industry, including pharmaceuticals, medical devices, foods, and beauty & cosmetics businesses.
Contact details:
Address: 187 Osongsaengmyeong2(i)-ro, Gangoe-myeon, Cheongwon-gun, Chungcheongbuk-do, 363-951 Korea
Tel: +82-43-713-8000 ~ 8005
KHIDI’s Soonman KWON outlines the public health R&D funding landscape in Korea, plans to increase Korea’s capacity to develop and produce its own vaccines in the wake of the COVID-19…
Kyung Kook Lee, chairman of KMDIA, explains the association’s role in working with the medical devices industry to boost both the local market and to raise Korea’s profile as a…
Jung Hyun Yun lifts the lid on Biosolution’s new stem cell technology that could revolutionize the treatment of cartilage-related ailments, such as osteoarthritis. He also discusses the plans for global…
Antimicrobial resistance (AMR) is a global health concern that we are increasingly understanding the consequences of and pulling together to try and keep under control. Korea is one of the…
Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market,…
The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced…
Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for…
Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four…
Yong-Ik Kim, president of Korea’s National Health Insurance Service (NHIS), provides an insight into the implementation of the upcoming MoonCare reforms, the government’s strategy to ensure the expansion of coverage…
Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug development. He also…
Sean Kim, senior director at the Korea Research-Based Pharma Industry Association (KRPIA) gives his assessment of the role of MNCs within the pharma industry in South Korea. At the…
Roger Zbinden, head of the Swiss Business Hub Korea, explains their efforts to raise the profile of the South Korean market for Swiss business. Dr Zbinden also provides his insights…
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
See our Cookie Privacy Policy Here